References
1. Read, B. and P. Sylla, Aggressive Colorectal Cancer in the Young. Clin Colon Rectal Surg, 2020. 33(5): p. 298-304.
2. Recio-Boiles, A. and B. Cagir, Colon Cancer, in StatPearls. 2021: Treasure Island (FL).
3. Dekker, E., et al., Colorectal cancer. Lancet, 2019. 394(10207): p. 1467-1480.
4. Gu, M. and S. Thapa, Colorectal cancer in the United States and a review of its heterogeneity among Asian American subgroups. Asia Pac J Clin Oncol, 2020. 16(4): p. 193-200.
5. Fisher, K.W., et al., Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. Future Oncol, 2015. 11(19): p. 2711-2719.
6. Hardingham, J.E., et al., Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer--20 Years of Progress. Mol Med, 2015. 21 Suppl 1: p. S25-31.
7. Edgar, B.A., From cell structure to transcription: Hippo forges a new path. Cell, 2006. 124(2): p. 267-73.
8. Hong, A.W., Z. Meng, and K.L. Guan, The Hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol, 2016. 13(6): p. 324-37.
9. Meng, Z., T. Moroishi, and K.L. Guan, Mechanisms of Hippo pathway regulation. Genes Dev, 2016. 30(1): p. 1-17.
10. Moroishi, T., C.G. Hansen, and K.L. Guan, The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer, 2015. 15(2): p. 73-79.
11. Matallanas, D., et al., RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell, 2007. 27(6): p. 962-75.
12. Murakami, S., et al., Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene, 2017. 36(9): p. 1232-1244.
13. Wu, H., et al., Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma. Tumour Biol, 2016. 37(10): p. 13499-13508.
14. Liu, J.Y., et al., Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer, 2013. 13: p. 349.
15. Wang, Y., et al., Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci, 2010. 101(5): p. 1279-85.
16. Yan, H., et al., Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy. Oncol Rep, 2018. 39(4): p. 1671-1681.
17. Konsavage, W.M., Jr., et al., Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem, 2012. 287(15): p. 11730-9.
18. Yuan, M., et al., Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ, 2008. 15(11): p. 1752-9.
19. Barry, E.R., et al., Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature, 2013. 493(7430): p. 106-10.
20. Cottini, F., et al., Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med, 2014. 20(6): p. 599-606.
21. Xu, Z., et al., YAP Levels Combined with Plasma CEA Levels Are Prognostic Biomarkers for Early-Clinical-Stage Patients of Colorectal Cancer. Biomed Res Int, 2019. 2019: p. 2170830.
22. Li, H.L., et al., A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression. J Cancer Res Clin Oncol, 2021. 147(6): p. 1569-1585.
23. Dong, T., et al., High cytoplasmic YAP1 expression predicts a poor prognosis in patients with colorectal cancer. PeerJ, 2020. 8.
24. Wang, Y., et al., Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol, 2013. 34(4): p. 2169-74.
25. Yang, R., et al., Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer. Immunology, 2018. 155(2): p. 263-272.
26. Wang, L., et al., Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One, 2013. 8(6): p. e65539.
27. Zhang, S., et al., Loss of Yes-associated Protein Represents an Aggressive Subtype of Colorectal Cancer. J Cancer, 2019. 10(3): p. 689-696.
28. Tierney, J.F., et al., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007. 8: p. 16.
29. Kim, J.Y., et al., VGLL4 with low YAP expression is associated with favorable prognosis in colorectal cancer. Apmis, 2020. 128(10): p. 543-551.
30. Ou, C., et al., MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer. Cancer Letters, 2017. 399: p. 53-63.
31. Sun, Z., et al., YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer. Oncogene, 2019. 38(14): p. 2627-2644.
32. Kim, D.H., et al., Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma. Histol Histopathol, 2013. 28(11): p. 1483-90.
33. Weinstein, P.S., et al., Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol, 1984. 19(3): p. 193-8.
34. Duffy, M.J., et al., Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer, 2007. 43(9): p. 1348-60.
35. Zhou, D., et al., Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A, 2011. 108(49): p. E1312-20.
36. Steinhardt, A.A., et al., Expression of Yes-associated protein in common solid tumors. Hum Pathol, 2008. 39(11): p. 1582-9.
1. READ B, SYLLA P. Aggressive Colorectal Cancer in the Young[J]. Clin Colon Rectal Surg, 2020,33(5):298-304.
2. RECIO-BOILES A, CAGIR B. Colon Cancer. StatPearls. Treasure Island (FL)2021.
3. DEKKER E, TANIS P J, VLEUGELS J L A, et al. Colorectal cancer[J]. Lancet, 2019,394(10207):1467-1480.
4. GU M, THAPA S. Colorectal cancer in the United States and a review of its heterogeneity among Asian American subgroups[J]. Asia Pac J Clin Oncol, 2020,16(4):193-200.
5. FISHER K W, LOPEZ-BELTRAN A, MONTIRONI R, et al. Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus[J]. Future Oncol, 2015,11(19):2711-2719.
6. HARDINGHAM J E, GROVER P, WINTER M, et al. Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer--20 Years of Progress[J]. Mol Med, 2015,21 Suppl 1:S25-31.
7. EDGAR B A. From cell structure to transcription: Hippo forges a new path[J]. Cell, 2006,124(2):267-273.
8. HONG A W, MENG Z, GUAN K L. The Hippo pathway in intestinal regeneration and disease[J]. Nat Rev Gastroenterol Hepatol, 2016,13(6):324-337.
9. MENG Z, MOROISHI T, GUAN K L. Mechanisms of Hippo pathway regulation[J]. Genes Dev, 2016,30(1):1-17.
10. MOROISHI T, HANSEN C G, GUAN K L. The emerging roles of YAP and TAZ in cancer[J]. Nat Rev Cancer, 2015,15(2):73-79.
11. MATALLANAS D, ROMANO D, YEE K, et al. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein[J]. Mol Cell, 2007,27(6):962-975.
12. MURAKAMI S, SHAHBAZIAN D, SURANA R, et al. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma[J]. Oncogene, 2017,36(9):1232-1244.
13. WU H, LIU Y, JIANG X W, et al. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma[J]. Tumour Biol, 2016,37(10):13499-13508.
14. LIU J Y, LI Y H, LIN H X, et al. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder[J]. BMC Cancer, 2013,13:349.
15. WANG Y, DONG Q, ZHANG Q, et al. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer[J]. Cancer Sci, 2010,101(5):1279-1285.
16. YAN H, QIU C, SUN W, et al. Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy[J]. Oncol Rep, 2018,39(4):1671-1681.
17. KONSAVAGE W M, JR., KYLER S L, RENNOLL S A, et al. Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells[J]. J Biol Chem, 2012,287(15):11730-11739.
18. YUAN M, TOMLINSON V, LARA R, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast[J]. Cell Death Differ, 2008,15(11):1752-1759.
19. BARRY E R, MORIKAWA T, BUTLER B L, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP[J]. Nature, 2013,493(7430):106-110.
20. COTTINI F, HIDESHIMA T, XU C, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers[J]. Nat Med, 2014,20(6):599-606.
21. XU Z, WANG H, GAO L, et al. YAP Levels Combined with Plasma CEA Levels Are Prognostic Biomarkers for Early-Clinical-Stage Patients of Colorectal Cancer[J]. Biomed Res Int, 2019,2019:2170830.
22. LI H L, LI Q Y, JIN M J, et al. A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression[J]. J Cancer Res Clin Oncol, 2021,147(6):1569-1585.
23. DONG T, YUAN Y, XIANG X, et al. High cytoplasmic YAP1 expression predicts a poor prognosis in patients with colorectal cancer[J]. PeerJ, 2020,8.
24. WANG Y, XIE C, LI Q, et al. Clinical and prognostic significance of Yes-associated protein in colorectal cancer[J]. Tumour Biol, 2013,34(4):2169-2174.
25. YANG R, CAI T-T, WU X-J, et al. Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer[J]. Immunology, 2018,155(2):263-272.
26. WANG L, SHI S, GUO Z, et al. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells[J]. PLoS One, 2013,8(6):e65539.
27. ZHANG S, WEI Q, YANG Y, et al. Loss of Yes-associated Protein Represents an Aggressive Subtype of Colorectal Cancer[J]. J Cancer, 2019,10(3):689-696.
28. TIERNEY J F, STEWART L A, GHERSI D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007,8:16.
29. KIM J Y, KIM E K, LEE W M, et al. VGLL4 with low YAP expression is associated with favorable prognosis in colorectal cancer[J]. Apmis, 2020,128(10):543-551.
30. OU C, SUN Z, PENG Q, et al. MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer[J]. Cancer Letters, 2017,399:53-63.
31. SUN Z, OU C, LIU J, et al. YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer[J]. Oncogene, 2019,38(14):2627-2644.
32. KIM D H, KIM S H, LEE O J, et al. Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma[J]. Histol Histopathol, 2013,28(11):1483-1490.
33. WEINSTEIN P S, SKINNER M, SIPE J D, et al. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases[J]. Scand J Immunol, 1984,19(3):193-198.
34. DUFFY M J, VAN DALEN A, HAGLUND C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use[J]. Eur J Cancer, 2007,43(9):1348-1360.
35. ZHOU D, ZHANG Y, WU H, et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance[J]. Proc Natl Acad Sci U S A, 2011,108(49):E1312-1320.
36. STEINHARDT A A, GAYYED M F, KLEIN A P, et al. Expression of Yes-associated protein in common solid tumors[J]. Hum Pathol, 2008,39(11):1582-1589.